Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
Abstract Background Carcinoid heart disease is a rare disease which develops in patients with functional neuroendocrine tumors in an advanced tumor state. Patients diagnosed with carcinoid heart disease have a poor longtime prognosis with respect to morbidity and mortality and long-term data on pati...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-10739-z |
| _version_ | 1797845889235025920 |
|---|---|
| author | Eva Grundmann Alessandra Curioni-Fontecedro Emanuel Christ Alexander R. Siebenhüner |
| author_facet | Eva Grundmann Alessandra Curioni-Fontecedro Emanuel Christ Alexander R. Siebenhüner |
| author_sort | Eva Grundmann |
| collection | DOAJ |
| description | Abstract Background Carcinoid heart disease is a rare disease which develops in patients with functional neuroendocrine tumors in an advanced tumor state. Patients diagnosed with carcinoid heart disease have a poor longtime prognosis with respect to morbidity and mortality and long-term data on patient outcomes are lacking. Methods and results In this retrospective study, we analyzed outcomes of 23 patients with carcinoid heart disease enrolled into the SwissNet database. We observed that early diagnosis with echocardiographic surveillance of carcinoid heart disease during the course of the neuroendocrine tumor disease was beneficial to overall survival of patients. Conclusion Through nationwide patient enrollment, the SwissNet registry is a powerful data tool to identify, follow-up and evaluate long-term patient outcomes in patients with rare neuroendocrine tumor driven pathologies including carcinoid heart syndrome with observational methods enabling better therapy optimization to improve patient`s long-term perspectives and survival. In line with the current ESMO recommendations, our data proposes that heart echocardiography should be included as part of the general physical assessment in patients with newly diagnosed NET. |
| first_indexed | 2024-04-09T17:47:19Z |
| format | Article |
| id | doaj.art-95f4b791acac48cb842bfdea0c1cbaf8 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-09T17:47:19Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-95f4b791acac48cb842bfdea0c1cbaf82023-04-16T11:17:00ZengBMCBMC Cancer1471-24072023-04-012311910.1186/s12885-023-10739-zOutcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohortEva Grundmann0Alessandra Curioni-Fontecedro1Emanuel Christ2Alexander R. Siebenhüner3Department of Medical Oncology and Hematology, University Hospital Zurich and University ZurichDepartment of Medical Oncology and Hematology, University Hospital Zurich and University ZurichDepartment of Endocrinology, Diabetes, and Metabolism, Basel University Hospital, University of BaselDepartment of Medical Oncology and Hematology, University Hospital Zurich and University ZurichAbstract Background Carcinoid heart disease is a rare disease which develops in patients with functional neuroendocrine tumors in an advanced tumor state. Patients diagnosed with carcinoid heart disease have a poor longtime prognosis with respect to morbidity and mortality and long-term data on patient outcomes are lacking. Methods and results In this retrospective study, we analyzed outcomes of 23 patients with carcinoid heart disease enrolled into the SwissNet database. We observed that early diagnosis with echocardiographic surveillance of carcinoid heart disease during the course of the neuroendocrine tumor disease was beneficial to overall survival of patients. Conclusion Through nationwide patient enrollment, the SwissNet registry is a powerful data tool to identify, follow-up and evaluate long-term patient outcomes in patients with rare neuroendocrine tumor driven pathologies including carcinoid heart syndrome with observational methods enabling better therapy optimization to improve patient`s long-term perspectives and survival. In line with the current ESMO recommendations, our data proposes that heart echocardiography should be included as part of the general physical assessment in patients with newly diagnosed NET.https://doi.org/10.1186/s12885-023-10739-zCHDEchocardiographyHedinger syndromeNETNeuroendocrine tumorsNeuroendocrine treatment |
| spellingShingle | Eva Grundmann Alessandra Curioni-Fontecedro Emanuel Christ Alexander R. Siebenhüner Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort BMC Cancer CHD Echocardiography Hedinger syndrome NET Neuroendocrine tumors Neuroendocrine treatment |
| title | Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort |
| title_full | Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort |
| title_fullStr | Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort |
| title_full_unstemmed | Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort |
| title_short | Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort |
| title_sort | outcome of carcinoid heart syndrome in patients enrolled in the swissnet cohort |
| topic | CHD Echocardiography Hedinger syndrome NET Neuroendocrine tumors Neuroendocrine treatment |
| url | https://doi.org/10.1186/s12885-023-10739-z |
| work_keys_str_mv | AT evagrundmann outcomeofcarcinoidheartsyndromeinpatientsenrolledintheswissnetcohort AT alessandracurionifontecedro outcomeofcarcinoidheartsyndromeinpatientsenrolledintheswissnetcohort AT emanuelchrist outcomeofcarcinoidheartsyndromeinpatientsenrolledintheswissnetcohort AT alexanderrsiebenhuner outcomeofcarcinoidheartsyndromeinpatientsenrolledintheswissnetcohort |